Serum 25-hydroxyvitamin D in the VITamin D and OmegA-3 TriaL (VITAL): Clinical and demographic characteristics associated with baseline and change with randomized vitamin D treatment.

Plain-language guide to PMID 31669447 (2019): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc in 15,804 participants.

Key Facts

PMID: 31669447
Journal: Contemporary clinical trials
Year: 2019
Study type: Randomized Controlled Trial
Authors: Luttmann-Gibson H et al. (17 authors)
DOI: 10.1016/j.cct.2019.105854
Registered trial: NCT01169259

What This Study Did, in Plain Language

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

Here the researchers examine baseline and change in 25-hydroxyvitamin D (25(OH)D) and related biomarkers with randomized treatment and by clinical factors.

Who Took Part

According to the abstract, 15,804 participants were involved.

By PubMed's age tags, the people studied were middle-aged adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

Blinding on both sides kept the participants and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.

A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.

Calcium and parathyroid hormone (iPTH) were measured by chemiluminescence and spectrophotometry respectively.

What Was Measured

Topics PubMed links to this paper include Age Factors, Biomarkers, Black or African American, Body Mass Index, Calcium, Cardiovascular Diseases and Cholecalciferol.

Author keywords: 25-hydroxyvitamin D, Parathyroid hormone, Seasonal effects, VITAL trial and Vitamin D.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 15,804 participants.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 10 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2019 (Contemporary clinical trials), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.

Our Notes on the Compound

Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.

Vitamin D, K2, Magnesium and Zinc in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.